aTyr Pharma's Efzofitimod Fails to Meet Goals in Pulmonary Sarcoidosis Trial
aTyr Pharma's Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis did not meet its primary endpoint but showed clinical benefits such as improved lung scores and steroid withdrawal, leading the company to plan discussions with the FDA on future development.